Goldman Sachs Group Inc. Sells 139,658 Shares of Fulcrum Therapeutics, Inc. $FULC

Key Points

• Goldman Sachs Group Inc. has decreased its holdings in Fulcrum Therapeutics by 25.8%, owning 402,600 shares after selling 139,658 shares in the first quarter.
• Institutional investors collectively own 89.83% of Fulcrum Therapeutics, with several firms adjusting their stakes in the company.
• Fulcrum Therapeutics recently reported an EPS of ($0.28), surpassing the consensus estimate of ($0.29), and maintains a consensus "Buy" rating with an average target price of $9.60.

Goldman Sachs Group Inc. reduced its position in shares of Fulcrum Therapeutics, Inc. (NASDAQ:FULC - Free Report) by 25.8% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 402,600 shares of the company's stock after selling 139,658 shares during the period. Goldman Sachs Group Inc. owned 0.75% of Fulcrum Therapeutics worth $1,159,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the company. Acadian Asset Management LLC boosted its position in shares of Fulcrum Therapeutics by 865.0% in the first quarter. Acadian Asset Management LLC now owns 344,561 shares of the company's stock valued at $989,000 after acquiring an additional 308,854 shares during the period. Jacobs Levy Equity Management Inc. bought a new position in shares of Fulcrum Therapeutics during the 1st quarter worth about $425,000. BNP Paribas Financial Markets bought a new position in shares of Fulcrum Therapeutics during the 4th quarter worth about $38,000. Exome Asset Management LLC raised its position in shares of Fulcrum Therapeutics by 143.0% during the first quarter. Exome Asset Management LLC now owns 689,137 shares of the company's stock valued at $1,985,000 after buying an additional 405,538 shares during the last quarter. Finally, Millennium Management LLC lifted its stake in shares of Fulcrum Therapeutics by 224.0% in the fourth quarter. Millennium Management LLC now owns 76,123 shares of the company's stock valued at $358,000 after buying an additional 52,628 shares during the period. 89.83% of the stock is owned by institutional investors.

Fulcrum Therapeutics Stock Performance

Shares of Fulcrum Therapeutics stock traded up $0.06 during trading on Monday, reaching $7.45. The company's stock had a trading volume of 271,490 shares, compared to its average volume of 459,147. Fulcrum Therapeutics, Inc. has a one year low of $2.32 and a one year high of $8.50. The stock has a 50-day moving average price of $7.04 and a two-hundred day moving average price of $5.76.

Fulcrum Therapeutics (NASDAQ:FULC - Get Free Report) last issued its quarterly earnings data on Tuesday, July 29th. The company reported ($0.28) EPS for the quarter, topping analysts' consensus estimates of ($0.29) by $0.01. On average, research analysts anticipate that Fulcrum Therapeutics, Inc. will post -0.16 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on FULC. HC Wainwright raised Fulcrum Therapeutics from a "neutral" rating to a "buy" rating and upped their price target for the company from $4.00 to $12.00 in a report on Tuesday, July 29th. Piper Sandler reaffirmed an "overweight" rating and set a $9.00 price objective (up from $6.00) on shares of Fulcrum Therapeutics in a report on Thursday, May 29th. Wall Street Zen downgraded shares of Fulcrum Therapeutics from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Finally, Royal Bank Of Canada raised their price objective on shares of Fulcrum Therapeutics from $4.00 to $5.00 and gave the stock a "sector perform" rating in a report on Wednesday, July 30th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Hold rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus price target of $9.60.

Fulcrum Therapeutics Profile

Fulcrum Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial.